Cargando…
Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial
INTRODUCTION: Prior to investing in a large, multicentre randomised controlled trial (RCT), the National Institute for Health Research in the UK called for an evaluation of the feasibility and value for money of undertaking a trial on intravenous immunoglobulin (IVIG) as an adjuvant therapy for seve...
Autores principales: | Soares, Marta O, Welton, Nicky J, Harrison, David A, Peura, Piia, Shankar-Hari, Manu, Harvey, Sheila E, Madan, Jason, Ades, Anthony E, Rowan, Kathryn M, Palmer, Stephen J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271457/ https://www.ncbi.nlm.nih.gov/pubmed/25434816 http://dx.doi.org/10.1186/s13054-014-0649-z |
Ejemplares similares
-
Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses
por: Welton, Nicky J., et al.
Publicado: (2015) -
Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
por: Hamano, Nobuyuki, et al.
Publicado: (2013) -
External validity of rct evidence in cost-effectiveness analyses. A review of recent technology appraisals for nice and proposed methods of adjustment
por: Mantopoulos, Theodoros, et al.
Publicado: (2015) -
Evidence Synthesis for Decision Making 6: Embedding Evidence Synthesis in Probabilistic Cost-effectiveness Analysis
por: Dias, Sofia, et al.
Publicado: (2013) -
Use of Hydrocortisone Based on Plasma Biomarkers in Patients with Septic Shock: Another One Bites the Dust?
por: Møller, Morten Hylander, et al.
Publicado: (2020)